Michael Morris, MD, the Steven A. Greenberg Chair in Prostate Cancer Research at Memorial Sloan Kettering Cancer Center in New York. (IMAGE)

Alliance for Clinical Trials in Oncology

Michael Morris, MD, the Steven A. Greenberg Chair in Prostate Cancer Research at Memorial Sloan Kettering Cancer Center in New York.

Caption

“This study is the first to show how an individual’s genetics can impact how abiraterone is metabolized. These findings could lead to optimized dosing strategies in the future, rather than giving the same dose of the drug to everyone, as we do now,” said author Michael Morris, MD, the Steven A. Greenberg Chair in Prostate Cancer Research at Memorial Sloan Kettering Cancer Center in New York.

Credit

Courtesy Memorial Sloan Kettering Cancer Center

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.